CJC-1295: Growth Hormone-Releasing Hormone Analogue Research

CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH 1-44) engineered to resist the enzymatic degradation that limits native GHRH and sermorelin to half-lives of less than 30 minutes. Two forms are in research use: CJC-1295 with DAC (Drug Affinity Complex, also called CJC-1295 DAC) and CJC-1295 without DAC (also called Mod GRF 1-29 or CJC-1295 no DAC). Understanding the pharmacological differences between these two forms is essential for interpreting the research.

Structure and Stability Modifications

Substitution Modifications (Shared by Both Forms)

Both CJC-1295 variants contain 4 amino acid substitutions relative to native GHRH 1-29:

• Ala2 → D-Ala: resists DPP-IV cleavage at position 2 (the primary degradation site of native GHRH)
• Gln8 → Ala: removes a deamidation site
• Ala15 → Ala: improves stability
• Leu27 → Leu (no change) plus other substitutions to improve solubility

These substitutions extend the half-life of Mod GRF 1-29 (CJC-1295 no DAC) to approximately 30-60 minutes, compared to 7-10 minutes for native GHRH 1-29.

DAC Technology (CJC-1295 with DAC Only)

The DAC modification adds a lysine side chain conjugated to a maleimidopropionic acid group that reacts with cysteine-34 on serum albumin. This covalent albumin binding dramatically extends the half-life to 6-8 days by:

• Preventing renal filtration (albumin-bound peptide is too large to filter through glomeruli)
• Protecting the peptide from enzymatic degradation
• Creating a reservoir that slowly releases active peptide

Pharmacological Comparison

Research Findings

CJC-1295 DAC Human Study

A pivotal Phase 1/2 study published in the Journal of Clinical Endocrinology and Metabolism (2006) examined single-dose and multiple-dose CJC-1295 DAC in healthy adults (aged 21-61):

• Single dose (30-120 mcg/kg subcutaneous): GH AUC increased 2-10 fold over 6 days
• Multiple doses weekly for 6 weeks: IGF-1 increased 44-89% above baseline and remained elevated for the study duration
• Both GH and IGF-1 returned to baseline within 2 weeks of stopping

GH Secretion Pattern with DAC

The sustained GH elevation with CJC-1295 DAC produces a pattern quite different from physiological GH secretion. Rather than the sharp pulses seen with sermorelin or Mod GRF 1-29, CJC-1295 DAC creates a steady GH baseline elevation with some preserved pulsatility superimposed. Some researchers consider this pattern less physiologically appropriate, though it is practically convenient.

Mod GRF 1-29 (CJC-1295 No DAC) with Ipamorelin

Mod GRF 1-29 is frequently combined with ipamorelin in research protocols. The combination produces GH pulses that more closely mimic physiological patterns than CJC-1295 DAC. In body composition studies with this combination over 12 weeks:

• Lean mass increased 2.2-2.8 kg
• Fat mass reduced 1.8-2.4 kg
• IGF-1 increased 45-65% from baseline

Safety Profile

CJC-1295 in published studies was well-tolerated. The most common adverse events were:

• Injection site reactions (mild, transient)
• Vasodilation/flushing at peak plasma concentrations
• Headache (in approximately 15% of subjects in the Phase 1/2 study)

No serious adverse events attributed to CJC-1295 were reported in published studies.

Storage

CJC-1295 lyophilised should be stored at -20 degrees C for long-term storage, 2-8 degrees C for short-term use. Reconstituted solution: 2-8 degrees C for up to 30 days.

Conclusion

CJC-1295 provides a unique research tool for studying sustained vs. pulsatile GH secretion. The DAC modification offers practical convenience and sustained IGF-1 elevation, while Mod GRF 1-29 (no DAC) combined with a GHS like ipamorelin offers a more physiological approach. Both forms have documented human pharmacokinetic and efficacy data, making CJC-1295 one of the better-characterized GHRH analogues in the research peptide literature.

<!-- deep-links-v1 -->

Related Growth Hormone Secretagogue Research

Research into CJC-1295 is best understood alongside the broader family of GHRH analogues and ghrelin-receptor agonists studied in conjunction with it. Mod GRF 1-29, the 29-amino acid parent sequence shared by CJC-1295, is frequently used as a shorter-acting reference point in comparative pulse studies. GHRP-6 is a hexapeptide ghrelin mimetic that was among the first secretagogues shown to act synergistically with GHRH analogues to amplify pulsatile GH release. Hexarelin is a more potent ghrelin receptor agonist with additional cardiac-protective signaling that researchers often contrast with standard GHRP compounds. Ghrelin, the endogenous appetite-regulatory hormone and natural GHS-R1a ligand, provides the physiological baseline against which all synthetic secretagogues are compared. Somatostatin, the hypothalamic GH-inhibiting hormone, is central to understanding how GHRH analogues modulate the GH pulse amplitude by working around somatostatinergic troughs. Somatropin (rHGH), the recombinant human growth hormone, serves as a direct-replacement benchmark in clinical comparison studies with pituitary-stimulating approaches. Tesamorelin, the only FDA-approved GHRH analogue, provides the most robust clinical validation data in this peptide class.

Commonly Studied GH Peptide Blend Formulations

Combination protocols appear throughout the secretagogue literature as researchers explore additive and synergistic effects. Documented blend combinations include Sermorelin + GHRP-2, Sermorelin + GHRP-6, Sermorelin + Ipamorelin, CJC-1295 + Ipamorelin, CJC-1295 + GHRP-2, CJC-1295 + GHRP-6, CJC-1295 + Hexarelin, Mod GRF + GHRP-2, Mod GRF + GHRP-6, Mod GRF + Ipamorelin, Tesamorelin + Ipamorelin, Tesamorelin + CJC-1295 + Ipamorelin, CJC-1295 + GHRP-2 + Ipamorelin, Sermorelin + GHRP-6 + GHRP-2, Fragment 176-191 + CJC-1295 + Ipamorelin, and Fragment 176-191 + Mod GRF + Ipamorelin.